Heidelberg Pharma AG: Heidelberg Pharma AG (WL6, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumour resistance mechanisms. The platform can be applicable across many cancer types and has a specific genetic biomarker that confers high tumour cell susceptibility to the therapy in many cancer types. Heidelberg Pharma is accelerating development of an internal pipeline of ATACs. Lead product HDP-101, for blood cancer, is expected to enter phase I studies by end 2020. It also has several out-licensed programs using ATAC and antibody drug conjugate technology expected to generate long term income streams and early technology validation
Based in...
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology, Men's Health
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Schriesheimer Straße 101
Ladenburg, 68526

Company Participants at European Biotech Investor Day 2020

  • Jan Schmidt-Brand, CEO

Top 10 Holders of Heidelberg Pharma AG

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Gutmann Finanz Strategien AG 0.06 17,800 0.08 Funds 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.